WATCH: The Valeant Collapse Goes Much Deeper
Valeant PharmaceuticalsWritten by Ophir Gottlieb, 11-05-2015
Valeant Pharma is collapsing on fraud allegations. That's what we've been told. But the stock's implosion goes ever further than that.
The article below goes into greater detail, but here's a video recap of the biggest breaking story in finance. I promise, you will leave this article with more knowledge than you came here with, including realities that nearly all of Wall St. has ignored.
We write one story a day and are starting to add videos like the one above to uncover new opportunities and break news. Join the fastest growing trading news and research portal in the world. Get Our (Free) News Alerts Once a Day.
Opinion: Valeant's entire mode of operation (acquire drug companies, slashing jobs, costs, and R&D and then raising drug prices) is over. Period. The company can no longer acquire any more companies nor can it raise prices.
This is the stock chart, and that high point is over $260.
First, the accusations are actually pretty simple and they read like this in plain English although somewhat simplified: Accusation: Valeant has literally booked revenue that didn't exist by creating a secret network of specialty pharmacies that it owned, then went ahead and sent drugs to them and counted those transfers as sales. Yes, an outright fraud. That's it.
Now, let's get to the issues before, during and after this crisis that are breathtaking.
Before the Accusations
I. Fact: Valeant is Not a Drug Company
CEO Michael Pearson reportedly believed that drug companies were terribly inefficient spending money on research and development that often went no where (Source: Fortune).
Instead, Valeant become focused on distribution, letting other firms do the R&D and then implemented a strategy of rapid acquisitions. After companies were acquired, staff was laid off and R&D was dismissed and prices on all drugs were raised. The end result was a company with an enormous amount of debt, but a stock price that was rising.
Here's the problem, debt is now an issue, and it could take Valeant down. A thorough discussion of debt is included below, below. But to give you taste, it looks like this (debt through time):
What can Valeant do if it can't borrow any more? That's how it grows. Here's an image of the company's exploding Goodwill -- which is the amount above fair market value it has paid for its acquisitions. We divide Goodwill by total assets in the chart below.
Do you thrive on understanding what's really going on in a company beyond headlines? Get Our (Free) News Alerts Once a Day.
II. Fact: Congress Was Already Investigating Valeant
August 14th: Even before this saga began, Valeant became the subject of vitriol due its immense price increases on two drugs to the tune of 525% and 212% that came overnight. Senator Bernie Sanders and Congressman Elijah Cummings requested information on the two price hikes but the company refused to furnish the documents saying the requested information was "highly proprietary and confidential" (Source: WSJ).
September 28th: A month and a half later, 18 Democrats on the House Committee on Oversight and Government Reform called for a subpoena of the company. The stock dropped ~15% in a day.
It takes more than click bait and a 140 characters to be an expert. Get free news alerts (once a day) from us and you will be the expert in the room. You will be powerful. Get Our (Free) News Alerts.
III. Fact: Price Gauging Was Massive
On October 5th, a Deutsche Bank analyst revealed that it wasn't just two two drugs but rather 54 other medicines in 2015 alone and by an average of 66%. Aside from the accusations, Wall St. analysts started noting that a revenue growth strategy based on price hikes of this magnitude was not sustainable. Again, this is all before the fraud accusations.
IV. Fact: Board Members of Largest Valeant Shareholders Resign
The $7.5 billion Sequoia fund had a nearly 30% weight in Valeant as of the end of June. The Wall Street Journal reports that Vinod Ahooja and Sharon Osberg stepped down from Sequoia Fund's independent board of directors and that the two "had raised concerns in recent months about whether Sequoia should have such a large position in the embattled pharmaceutical company" (Source: Barron's).
Biotech and technology data runs deeper than headlines and deeper than the data non-professionals have access to. That advantage is no longer acceptable to us. Get Our Free News Alerts Once a Day.
V. Fact: Debt Has Exploded
There's another issue, an inarguable issue, and issue openly admitted to and signed off by the CEO of Valeant. Here it is:
Valeant has nearly $31 billion in debt and just $1.4 billion in cash. The company's total market cap as of this writing is just $34 billion. The company has a additional "revolving credit facility" (think of it like a credit card) of $1.5 billion. Here's where it all falls apart:
Whatever happens to these fraud allegations, Valeant will not be raising prices again in the near future. The company has $2 billion in debt due in 2016, and other $2 due in 2017 and $4 billion due in 2018. Yes, that's $8 billion just in debt payments and bond redemptions (Source: Fortune).
If you're wondering whether this debt situation is normal for Valeant, the answer is unambiguously, no. Here's how the debt has exploded through time.
The main stream media doesn't have the vocabulary to understand breaking biotechnology. Get free news alerts (once a day) from us and you will be the expert in the room. Get Our (Free) News Alerts.
Debt is up 90% year-over-year. S&P downgraded Valeant on October 30th down to B+ from BB-. Here's what S&P said along with the downgrade:
"Given the multitude of legal, regulatory, and reputational issues that Valeant faces, we are revising our assessment of management and governance to 'weak' from 'fair,'
VI. Allegation: WHOA!
The accusation of specialty pharmacies that were owned by Valeant making fake orders to book false sales when drugs moved from one room to another room is the allegation. Here's how it is accused of going down:
R&O pharmacy is accusing Valeant of fraud and on a grand (grand) scale. The quick and dirty is that a sole proprietor, 64 year-old Russell Reitz, sold his pharmacy for $350,000 and even before the sale was completed, other pharmacies began using an R&O identification number to bill for prescriptions that R&O hadn't filled, sometimes for drugs the store didn't stock, turning in revenue of $230 million according to the court documents (Source: Bloomberg).
Before the sale was actually done, Reitz asked why Valeant had signed an insurance-company audit for the pharmacy that Reitz still controlled. The next day, Reitz received surprise visitors from a firm called Philidor RX Services.
Reitz's effort to learn who was selling drugs in his name -- peeling back, along the way, layers of corporate structures -- emerges in e-mails, letters and other documents filed in state court in Los Angeles, as well as in a lawsuit R&O filed against Valeant in federal court there early this month.
And thus the fraud allegations took off.
The media simply isn't equipped to understand the stock market beyond headlines. Try CML Pro. No credit Card. No Payment Info. Just the Power.
VII. Fact: Philidor Failed California's Sniff Test
Philidor is a mail-order pharmacy with licenses in 46 states But one state, California, said no, and here's why:
"The board, on its website, said Philidor had made misleading statements about its ownership, failing to include information on four out of five partners." For context, fewer than 1% of such applications are denied, according California's board executive officer, Virginia Herold.
VIII. Fact: Valeant Cuts Ties with Philidor
Valeant has cut ties with Philidor a week ago but the announcement only came hours only after the nation's two largest pharmacy benefit providers, CVS Health and Express Scripts, said that they had ended all interactions with the company, citing its business practices (Source: NBC).
Now you decide. Is this company a fraud? Given the debt and price hike situation which disrupts its entire mode of operation, does it matter any more? Or, is this the greatest buying opportunity in a biotech in years?
THE NEXT HUGE WINNERS
Friends, this is the information that the top 0.1% use. This is how the greatest transfer in wealth we have ever experienced has moved money to the top 0.1% from everybody else. It's just access to information, that's all. Our purpose is to provide institutional research to all investors and break the information monopoly held by the top .1%. Here's how we do it:
True margins, revenue and profits, the kind that turn companies from small caps into mega caps, the kind that see stocks double, triple or even quadruple, that only occurs when two critical phenomena collide:
To find the 'next Apple' or 'next Google' we have to get ahead of the curve. This is what CML Pro does. Our research sits side-by-side with Goldman Sachs, Morgan Stanley and the rest on professional terminals, but we are the anti-institution and break the information advantage the top .1% have.
Each company in our 'Top Picks' is the single winner in an exploding thematic shift like artificial intelligence, Internet of Things, the cloud, drones, biotech and more. In fact, here are just two of the trends that will radically affect the future that we are ahead of:
The Internet of Things (IoT) market will be measured in trillions of dollars as of next year. CML Pro has named the top two companies that will benefit. Then there's cyber security:
Market correction or not, recession or not, the growth in this area is a near certainty, even if projections come down, this is happening. CML Pro has named the single best cyber security stock to benefit from this theme.
These are just two of the themes we have identified and this is just one of the fantastic reports CML Pro members get along with all the visual tools, the precious few thematic top picks for 2016, research dossiers and alerts. For a limited time we are offering CML Pro at a 90% discount for $10/mo. with a lifetime guaranteed rate. Join Us: Get the most advanced premium research delivered to your inbox along with access to visual tools and data that until now has only been made available to the top 1%.
Thanks for reading, friends.